In recent studies, 3,4‐methylenedioxymethylamphetamine (MDMA) has shown promise in the treatment of post‐traumatic stress disorder (PTSD) as an adjunct to post‐trauma psychological therapy. However, because of historical associations with its use as the recreational drug ecstasy, MDMA research remains a controversial subject. Dr Sessa discusses these controversies and describes a UK‐based MDMA/PTSD currently in development. Copyright © 2011 John Wiley & Sons, Ltd.